Navigation Links
Dialysis Corporation of America Announces Share Repurchase Program
Date:4/13/2009

LINTHICUM, Md., April 13 /PRNewswire-FirstCall/ -- Dialysis Corporation of America (Nasdaq: DCAI) announced that its Board of Directors has approved a stock repurchase program, effective April 13, 2009. Under the program, the company is authorized to repurchase up to $3 million of its outstanding shares of common stock from time to time, depending on market conditions, share price and other factors.

The stock purchases will be made out of available cash in open market transactions at the prevailing market price or through privately negotiated transactions.

"This stock repurchase program underscores the level of confidence we have in our company and is aligned with our commitment to deliver long-term shareholder value," said Thomas K. Langbein, Chairman of the Board.

The duration of the repurchase program is open-ended but may be suspended or discontinued at any time in the discretion of the company's management without prior notice. As of April 13, 2009, the company had approximately 9.6 million shares of common stock outstanding.

Dialysis Corporation of America owns and operates freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis services on a contract basis to certain hospitals located in the those states. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis services.

This release contains forward-looking statements that are subject to risks and uncertainties that could affect the business and prospects of the company and cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, increases in interest rates, the possible need for and availability of additional financing, the company's satisfying the covenants and conditions of its credit facility, certain delays beyond the company's control with respect to future business events, the highly competitive environment in the establishment and operation of dialysis centers, the ability to develop or acquire additional dialysis facilities, whether patient bases of the company's dialysis facilities can mature to provide profitability, the extensive regulation of dialysis operations, government rate determination for Medicare reimbursement, pricing pressure from private payors, and other risks detailed in the company's filings with the SEC, particularly as described in the company's annual report on Form 10-K for the fiscal year ended December 31, 2008. The historical results contained in this press release are not necessarily indicative of future performance of the company.

Other Dialysis Corporation of America press releases, corporate profile, corporate governance materials, quarterly and current reports, and other filings with the Securities and Exchange Commission are available on Dialysis Corporation of America's internet home page: http://www.dialysiscorporation.com.


'/>"/>
SOURCE Dialysis Corporation of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dialysis Corporation of America Announces Establishment of Clinical Grant Agreement with the University of Cincinnati, College of Medicine
2. DaVitas IMPACT Program Reduces Mortality for New Dialysis Patients
3. Anti-microbial catheter to cut infection risk for dialysis patients
4. Dialysis Via Fistulas May Help Young or Old
5. NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year
6. Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results
7. Satellite Healthcare Researchers to Present at 29th Annual Dialysis Conference
8. Lowering BP in Dialysis Cases Cuts Heart Risks
9. Preparing for the Next Disaster: Dialysis Community Briefs Hill About Emergency Response
10. High-flux hemodialysis prolongs survival in many patients with CKD
11. Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CT (PRWEB) , ... March 28, 2017 , ... ... devices, announces today that the University of Pittsburgh Medical Center (UPMC) will acquire ... and Western Pennsylvania. , The program, developed in association with efforts by the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the ... care can be limited while the desire to conquer breakouts and eliminate skincare stress ... for every customer online, today released its inaugural survey on the State of Acne ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly ... professionals in the country to sit on the 2017 National Advisory Board for Allergan’s ... years Dr. Harper helped propel the clinic from a small start-up to number 78 ...
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... Public ... and across a variety of business channels. , While many results are clear, ... any public relations program. , When it comes to measurement, firms should always ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... MARLBOROUGH, Mass. , March 28, 2017 /PRNewswire/ ... RNAi company developing innovative therapeutics that address significant ... granted a patent from the Japan Patent Office ... targeting connective tissue growth factor (CTGF) for the ... not limited to skin fibrosis and proliferative retinopathy ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology: